PVEK (IMGN632)

Phase 1 Study of FLAG-Ida With Pivekimab Sunirine (PVEK [IMGN632]) for Adults With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
30 patients (estimated)
Sponsors
Fred Hutchinson / University of Washington Cancer Consortium
Collaborators
ImmunoGen, Inc.
Tags
Antibody Drug Conjugate (ADC), CD123
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1869
NCT Identifier
NCT06034470

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.